Protocol Ledger

NCT05816057 · Phase III · COMPLETED

A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

Interventional Phase III clinical trial protocol NCT05816057 sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-25 Enrollment: 476 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05816057
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)476 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05816057
Protocol FieldVerified Registry Value
NCT IdentifierNCT05816057
Consolidated Lead SponsorHangzhou Jiuyuan Gene Engineering Co. Ltd
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment476 participants (ACTUAL)
Registered Start Date2022-07-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05816057
Hospital Research SiteLocationSite Profile
The Second Affiliated Hospital of Anhui Medical UniversityHefei, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI